6:54 PM
 | 
May 09, 2014
 |  BC Extra  |  Top Story

Brodalumab meets in psoriasis Phase III

Amgen Inc. (NASDAQ:AMGN) and AstraZeneca plc (LSE:AZN; NYSE:AZN) said subcutaneous brodalumab met the co-primary endpoints compared to placebo in the Phase III AMAGINE-1 trial to treat moderate to severe plaque psoriasis. Both 140 mg and 210 mg...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >